However, to date, any variation in the expression levels of KLK14 during PCa progression after neoadjuvant hormonal therapy (NHT) has not been determined, and the molecular mechanisms supporting its protumorigenic effect in the prostate tumor microenvironment remain elusive. Here, KLK14 is linked to posterior cortical atrophy.